Study Condition(s): Migraine
A Study of Lasmiditan in Participants With Migraine
Study Alias: LAHC
The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.
The results of this study are not yet available.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participant must have a history of migraine with or without aura, for at least 1 year
- Participant must not have participated in a clinical study involving an investigational product within the last 30 days
- Participant must not have a history of or current irritable bowel syndrome
- Participant must not have used or intend to use any migraine prevention treatments (including, but not limited to, propranolol or topiramate) within 30 days of the first dose of study drug and during the study